In addition, an amphiphilic bifunctional PD-1/PD-L1 peptide antagonist has been developed to deliver doxorubicin and R848 after being cleaved by FAP, which in combination with PD-1 blockade therapy was observed to trigger a stronger immune response on activating immunogenic cell death and reprogramming tumor-associated macrophages (56). This evidence concerns the gene FAP and neoplasm.